AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 17 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A new vaccine candidate has been shown to cause tumor regression in experimental hepatoma, or liver cancer.
Researchers in the U.S. say animal model experiments have demonstrated that a recombinant strain of herpes simplex virus (HSV), R7020, causes tumors to recede when combined with ionizing radiation in animals with grafted human hepatoma.
"The HSV recombinant virus R7020 is an attenuated virus designed as a candidate for immunization against both HSV-1 and HSV-2 infections," R. Weichselbaum and coauthors, University of Chicago, noted recently, adding, "It was extensively tested in an experimental animal system and in a healthy human adult population without significant untoward effects."
Weichselbaum and colleagues tested R7020 in two common human primary liver cancer cell lines, Hep3B and Huh7, finding that after viral infection, R7020 replication was better in Hep3B cells. Correspondingly, investigators detected more tumor regression in animals transplanted with Hep3B cells than animals transplanted with Huh7 after R7020 therapy.
"Ionizing radiation combined with R7020 also showed differential results in antitumor efficacy ...
Source: HighBeam Research, Herpes simplex virus and radiation cause regression in...